Accès à distance ? S'identifier sur le proxy UCLouvain
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
Primary tabs
- Open access
- 73.23 K
Document type | Communication à un colloque (Conference Paper) – Présentation orale avec comité de sélection, Abstract |
---|---|
Access type | Accès libre |
Publication date | 2018 |
Language | Anglais |
Conference | "ESMO 20th World Congress on Gastrointestinal Cancer", (Spain) Barcelona (du 20/06/2018 au 23/06/2018) |
Journal information | "Annals of Oncology" - Vol. 29, no.Suppl 5, p. v105 (2018) |
Peer reviewed | yes |
issn | 0923-7534 |
e-issn | 1569-8041 |
Publisher | Oxford University Press (OUP) ((United Kingdom) Oxford) |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie UCL - (SLuc) Unité d'oncologie médicale |
Keywords | Oncology ; Hematology |
Links |
Bibliographic reference | Chiritescu, G ; Dumon, K ; Mercadé, T Macarulla ; Lang, I ; Vivas, C Santos ; et. al. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results.ESMO 20th World Congress on Gastrointestinal Cancer ((Spain) Barcelona, du 20/06/2018 au 23/06/2018). In: Annals of Oncology, Vol. 29, no.Suppl 5, p. v105 (2018) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/213117 |